Pfizer to collaborate with Imcyse on new immunotherapy programme
05-02-2021
Sigmapharm to appeal Pfizer and BMS’ Eliquis win
03-09-2020
US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
23-07-2020
Katherine Welles / Shutterstock.com
In a victory for Bristol-Myers Squibb (BMS) and Pfizer, a US federal judge has affirmed patents covering blood-thinner Eliquis (apixaban).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
BMS, Pfizer, generics, Eliquis, blockbuster drug, Sigmapharm, Sunshine Lake, Unichem, patent infringement, generic competition
